ArticleArXiv2025
Probabilistic Modeling of Antibody Kinetics Post Infection and Vaccination: A Markov Chain Approach.
Article in ArXiv, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Understanding dynamics of antibody levels is crucial for characterizing time-dependent response to immune events: either infections or vaccinations. The sequence and timing of these events significantly influence antibody level changes. Despite extensive interest in the recent years and many experimental studies, the effect of immune event sequences on antibody levels is not well understood. Moreover, disease or vaccination prevalence in the population are time-dependent. This, alongside the complexities of personal antibody kinetics, makes it arduous to analyze a sample immune measurement from a population. A rigorous mathematical characterization can inform public health decision making. Relevance to Life Sciences: A key result of this paper is an antibody response modeling framework for an arbitrary number of multiclass immune events-the first of its kind to the best of our knowledge. Our model is ideal for characterizing immune event sequences, referred to as personal trajectories. To illustrate our ideas, we apply our mathematical framework to longitudinal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) data from individuals with multiple documented infection and vaccination events. This approach is fully generalizable to other diseases that exhibit waning immunity, such as influenza, respiratory syncytial virus (RSV), and pertussis. Our work is an important step towards a comprehensive understanding of antibody kinetics for infectious diseases that could lead to an effective way to analyze the protective power of natural immunity or vaccination, predict missed immune events at an individual level, and inform booster timing recommendations. Mathematical Content: We design a rigorous mathematical characterization in terms of a time-inhomogeneous Markov chain model for event-to-event transitions coupled with a probabilistic framework for the post-event antibody kinetics of multiple immune events. Probabilistic models appropriately describe these measurements as they capture the natural variability in a population's antibody response. We build probability density models for population response since the emergence of a disease via a discrete convolution of immune state transmission probabilities and personal response models, repeatedly invoking the definition of conditional probability and the law of total probability. Importantly, our coupled framework simultaneously tracks immune state and antibody response. This novel modeling approach surpasses the susceptible-infected-recovered (SIR) characterizations by rigorously tracing the probability distribution of population antibody response across time.
Identifiers
40709298PMC12288654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.